GlassScriptPhysician profile
Alexa Kulick
NPI 1518625987
$2,819.36
in general payments reported to CMS, 2019-2025
18 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $168 · 2023: $1,126 · 2024: $1,051 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.66 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.45 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $629.90 | 2023-2025 | |
| Abbvie INC. | $567.58 | 2022-2025 | |
| Lilly USA, LLC | $300.83 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bausch Health US, LLC | $138.42 | 2023-2025 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $105.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $86.86 | 2022-2024 | Fasenra, Farxiga, Airsupra |
| Astellas Pharma US INC | $72.55 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $48.07 | 2024-2025 | |
| Becton, Dickinson and Company | $35.82 | 2024 | Bd Max System, Bd Max Instrument |
| Amgen INC. | $31.66 | 2024 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $28.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2022 | |
| Dexcom, INC. | $19.97 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $19.97 | 2024 | Immunocap |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.07 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $14.36 | 2022 | |
| Glaxosmithkline, LLC. | $12.74 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Kulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.